Jeffrey D Capello
CIK 1224108 · EVP & Chief Financial Officer · last filed 2026-10-02
Jeffrey D Capello is an EVP & Chief Financial Officer who has filed 67 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing shows the insider was granted $120.0K of NEOG on Oct 2, 2026. Across all open-market trades the lifetime net is −$13.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions. 22 SEC filings were submitted jointly with BOSTON SCIENTIFIC CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BSX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
620 LESHER PLACE
LANSING, MI 48912
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NEOG | Director | 42,306 | $12.21 | $516.6K | $100.2K | 11 | 2026-10-02 |
| AGIO | Director | 10,865 | $36.85 | $400.4K | $0 | 7 | 2026-06-23 |
| BIIB | EVP & Chief Financial Officer | 3,118 | $252.26 | $786.5K | $0 | 5 | 2020-02-14 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | — | — | — | $0 | 5 | 2018-07-06 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | — | — | — | $0 | 3 | 2017-07-27 |
| BSX | EVP & Chief Financial Officer | 447 | $45.58 | $20.4K | -$12.60M | 30 | 2013-12-02 |
| REVVITY, INC. (PKI) Delisted | SVP & CFO | 91,428 | $115.24 | $10.54M | -$989.9K | 4 | 2008-01-31 |
Recent Filings
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-02 | NEOG | Grant (A) | +9,804 | $120.0K | EDGAR |
| 2026-06-23 | AGIO | Mixed | +2,816 | $0 | EDGAR |
| 2026-06-16 | AGIO | Exer (M) | +1,976 | $0 | EDGAR |
| 2025-10-29 | NEOG | Exer (M) | +1,777 | $11.0K | EDGAR |
| 2025-10-28 | NEOG | Exer (M) | +2,025 | $12.5K | EDGAR |
| 2025-10-27 | NEOG | Grant (A) | +19,769 | $120.0K | EDGAR |
| 2025-10-09 | NEOG | Exer (M) | +2,071 | $11.7K | EDGAR |
| 2025-06-23 | AGIO | Mixed | +2,120 | $0 | EDGAR |
| 2025-06-17 | AGIO | Exer (M) | +1,977 | $0 | EDGAR |
| 2025-04-22 | NEOG | Buy (P) | +20,712 | $100.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.